Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F J Lofts

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|July 5, 2005
Myeloid growth factors in oncologyF J Lofts, R Pettengell
Cancer Treatment and Research|January 1, 1992
c-erbB2 amplification and overexpression in human tumorsF J Lofts, W J Gullick
European Journal of Pharmacology|May 21, 1982
Release of biologically active substances from non-aggregating human plateletsF J Lofts, P K Moore
Clinical Science (London, England : 1979)|January 1, 1983
Release of a 6-oxoprostaglandin E1-like substance from human plateletsF J Lofts, P K Moore
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam)F J Lofts, H Gogas, J L Mansi
Biochemical Pharmacology|September 15, 1983
The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1P K Moore, R J Griffiths, F J Lofts
Oncogene|October 1, 1993
Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivoF J Lofts, H C Hurst, M J Sternberg, et al.
The Journal of Pharmacy and Pharmacology|February 1, 1985
The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitroP S Wilsoncroft, F J Lofts, R J Griffiths, et al.
British Journal of Cancer|February 14, 1998
Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?H Gogas, F J Lofts, T R Evans, et al.
Anti-Cancer Drugs|July 18, 2000
Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxelP W Szlosarek, F J Lofts, R Pettengell, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|July 5, 2005
Myeloid growth factors in oncologyF J Lofts, R Pettengell
Cancer Treatment and Research|January 1, 1992
c-erbB2 amplification and overexpression in human tumorsF J Lofts, W J Gullick
European Journal of Pharmacology|May 21, 1982
Release of biologically active substances from non-aggregating human plateletsF J Lofts, P K Moore
Clinical Science (London, England : 1979)|January 1, 1983
Release of a 6-oxoprostaglandin E1-like substance from human plateletsF J Lofts, P K Moore
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam)F J Lofts, H Gogas, J L Mansi
Biochemical Pharmacology|September 15, 1983
The effect of some flavone drugs on the conversion of prostacyclin to 6-oxoprostaglandin E1P K Moore, R J Griffiths, F J Lofts
Oncogene|October 1, 1993
Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivoF J Lofts, H C Hurst, M J Sternberg, et al.
The Journal of Pharmacy and Pharmacology|February 1, 1985
The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitroP S Wilsoncroft, F J Lofts, R J Griffiths, et al.
British Journal of Cancer|February 14, 1998
Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?H Gogas, F J Lofts, T R Evans, et al.
Anti-Cancer Drugs|July 18, 2000
Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxelP W Szlosarek, F J Lofts, R Pettengell, et al.
Pageof 2